HighTower Advisors
LGND icon

HighTower Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

HighTower Advisors’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.22M Buy
11,133
+4,517
+68% +$894K ﹤0.01% 1651
2025
Q4 		$1.25M Buy
6,616
+29
+0.4% +$5.57K ﹤0.01% 1969
2025
Q3 		$1.17M Buy
6,587
+1,278
+24% +$190K ﹤0.01% 1996
2025
Q2 		$604K Buy
5,309
+9
+0.2% +$962 ﹤0.01% 2361
2025
Q1 		$557K Sell
5,300
-242
-4% -$27.4K ﹤0.01% 2367
2024
Q4 		$594K Buy
5,542
+400
+8% +$45.2K ﹤0.01% 2334
2024
Q3 		$518K Buy
5,142
+266
+5% +$26.8K ﹤0.01% 2374
2024
Q2 		$412K Buy
4,876
+262
+6% +$20.8K ﹤0.01% 2462
2024
Q1 		$337K Hold
4,614
– – ﹤0.01% 2589
2023
Q4 		$329K Buy
4,614
+47
+1% +$2.77K ﹤0.01% 2637
2023
Q3 		$275K Buy
4,567
+1,675
+58% +$110K ﹤0.01% 2666
2023
Q2 		$208K Buy
2,892
+122
+4% +$9.15K ﹤0.01% 2837
2023
Q1 		$203K Buy
+2,770
New +$197K ﹤0.01% 2744
2022
Q4 		– Sell
-4,756
Closed -$256K – 3437
2022
Q3 		$256K Buy
4,756
+5
+0.1% +$294 ﹤0.01% 2439
2022
Q2 		$265K Hold
4,751
– – ﹤0.01% 2443
2022
Q1 		$333K Sell
4,751
-124
-3% -$9K ﹤0.01% 2445
2021
Q4 		$469K Buy
4,875
+29
+0.6% +$2.68K ﹤0.01% 2201
2021
Q3 		$419K Buy
4,846
+32
+0.7% +$2.48K ﹤0.01% 2181
2021
Q2 		$394K Sell
4,814
-14
-0.3% -$1.17K ﹤0.01% 2186
2021
Q1 		$458K Sell
4,828
-117
-2% -$11.1K ﹤0.01% 2023
2020
Q4 		$308K Buy
4,945
+67
+1% +$3.82K ﹤0.01% 1911
2020
Q3 		$290K Buy
4,878
+119
+3% +$8.12K ﹤0.01% 1853
2020
Q2 		$332K Buy
+4,759
New +$302K ﹤0.01% 1671
2018
Q4 		– Sell
-1,587
Closed -$272K – 2300
2018
Q3 		$272K Buy
+1,587
New +$239K ﹤0.01% 1777
2017
Q4 		– Sell
-7,172
Closed -$613K – 2340
2017
Q3 		$613K Buy
+7,172
New +$568K 0.01% 1336

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

HighTower Advisors's LGND Position: Q1 2026 in Review

HighTower Advisors increased its Ligand Pharmaceuticals (LGND) stake by 68% in Q1 2026, buying an estimated $894K and bringing the position to 11,133 shares worth $2.22M. The position accounts for ﹤0.01% of the portfolio, ranked #1651.

HighTower Advisors first reported a position in LGND in Q3 2017 and has held it in 25 quarters since. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • HighTower Advisors held 11,133 shares of Ligand Pharmaceuticals worth $2.22M as of Q1 2026.
  • HighTower Advisors bought 4,517 Ligand Pharmaceuticals shares in Q1 2026, an estimated $894K.
  • Ligand Pharmaceuticals made up ﹤0.01% of HighTower Advisors's portfolio in Q1 2026, its #1651 holding.
  • HighTower Advisors first reported a position in Ligand Pharmaceuticals in Q3 2017 and has held it in 25 quarters since.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.